| Identification | Back Directory | [Name]
NGP 555 | [CAS]
1304630-27-0 | [Synonyms]
NGP 555
N-(5-ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)thiazol-2-amine
2-Thiazolamine, N-(5-ethyl-2,4-dimethylphenyl)-4-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]- | [Molecular Formula]
C23H23FN4S | [MOL File]
1304630-27-0.mol | [Molecular Weight]
406.52 |
| Chemical Properties | Back Directory | [Boiling point ]
574.9±60.0 °C(Predicted) | [density ]
1.24±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: soluble | [form ]
A solid | [pka]
5.16±0.61(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
NGP555, is a γ-secretase modulator. It significantly lowers Aβ42 in cell cultures. it also has shown good oral bioavailability and is brain-penetrant. | [in vivo]
NGP555 significantly lowers Aβ42 in the cerebrospinal fluid (CSF) at time points from 8 to10 hours post dose, panel B shows that reduction of Aβ cerebrospinal fluid (CSF) levels is significant at 3.75 mg/kg of NGP555 and above, and panel C shows an increase in Aβ38 levels at 15 mg/kg of NGP555 and above. When combining the reduction of Aβ42 with an increase in Aβ38, NGP555 is effective at raising CSF Aβ38/42 ratio at 1.87 mg/kg and above (panel D). NGP555-treated Tg mice show a significant protection from decline in performance with >65% less decline (P<0.005) when comparing the differential of Tg to non-Tg vehicle-treated mice. NGP555 also shows good oral bioavailability and is brain-penetrant with a brain:plasma ratio of ~0.93 in mice[1]. | [storage]
Store at -20°C |
|
|